Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Binding protein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    212 result(s) found for: Binding protein. Displaying page 5 of 11.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-005341-38 Sponsor Protocol Number: P04720 Start Date*: 2008-06-09
    Sponsor Name:Schering Plough Research Institute
    Full Title: A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing’s Sarcoma That Has Relapsed After Standard Systemic Therapy.
    Medical condition: Relapsed resectable and unresectable Osteosarcoma, Ewing Sarcoma.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) SE (Prematurely Ended) NO (Prematurely Ended) NL (Completed) IT (Completed) CZ (Completed) PT (Prematurely Ended) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000549-13 Sponsor Protocol Number: VX04-702-301 Start Date*: 2005-05-03
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis
    Medical condition: rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-003405-94 Sponsor Protocol Number: ABY-035-202 Start Date*: 2020-05-05
    Sponsor Name:ACELYRIN, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics a...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005226-26 Sponsor Protocol Number: HIPRA-HH-2 Start Date*: 2021-11-15
    Sponsor Name:HIPRA SCIENTIFIC
    Full Title: A Phase IIb, double-blind, randomized, active controlled, multi-centre, non-inferiority trial followed by a Phase III, single arm, open label trial, to assess immunogenicity and safety of a booster...
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004854-29 Sponsor Protocol Number: S245.4.008 Start Date*: 2007-09-21
    Sponsor Name:Abbott Products GmbH
    Full Title: One week double-blind, randomized, placebo-controlled, parallel-group, multi-center study with Creon® 25000 Minimicrospheres™ in subjects with pancreatic exocrine insufficiency after pancreatic sur...
    Medical condition: Pancreatic Exocrine Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033628 Pancreatic insufficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-004272-17 Sponsor Protocol Number: CLO-SCB-2019-003 Start Date*: 2021-03-25
    Sponsor Name:Clover Biopharmaceuticals AUS Pty Ltd
    Full Title: A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (S...
    Medical condition: SARS-CoV-2-mediated COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002204-33 Sponsor Protocol Number: C32322 Start Date*: 2007-03-02
    Sponsor Name:UCB Pharma S.A.
    Full Title: Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two dose...
    Medical condition: Relapsing forms of multiple slerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048393 Multiple sclerosis relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FI (Prematurely Ended) HU (Completed) SE (Prematurely Ended) GB (Completed) ES (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013657-14 Sponsor Protocol Number: AI438006 Start Date*: 2009-11-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004459-21 Sponsor Protocol Number: Co-ALS Start Date*: 2018-09-11
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
    Full Title: Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial
    Medical condition: Definite or probable amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    20.0 10029205 - Nervous system disorders 10052889 ALS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005752-16 Sponsor Protocol Number: CR0207-22 Start Date*: 2008-03-03
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with exemestane versus exemestane alone in post-menopausal women with recurrent or advanced, oestroge...
    Medical condition: recurrent or advanced oestrogen and/or progesterone receptor positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006198 Breast cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004263-47 Sponsor Protocol Number: EMR200104-011 Start Date*: 2013-03-01
    Sponsor Name:Merck KGaA
    Full Title: Open-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD) of adult onset
    Medical condition: Adult Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-000041-12 Sponsor Protocol Number: 49/11/EDG/TP2 Start Date*: 2012-03-23
    Sponsor Name:Zentiva k.s. Prague
    Full Title: Characterisation of ovulation inhibition and effects on metabolic parameters and haemostatic system of multiple administrations of a fixed-dose combination product containing 0.02 mg ethinylestradi...
    Medical condition: Investigation of ovulation inhibition, effects on metabolic parameters and haemostatic system for indication of contraception
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10030970 Oral contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005604-35 Sponsor Protocol Number: APEC1621B Start Date*: 2022-01-18
    Sponsor Name:National Cancer Institute (NCI)
    Full Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
    Medical condition: Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2019-002872-14 Sponsor Protocol Number: VAC079 Start Date*: 2019-11-12
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: A Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1 in healthy adults living in the UK
    Medical condition: Plasmodium vivax malaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10047665 Vivax malaria (benign tertian) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-000643-27 Sponsor Protocol Number: VAC071 Start Date*: 2019-09-23
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: A Phase IIa challenge study to assess efficacy of the Plasmodium vivax malaria vaccine candidates ChAd63 PvDBP and MVA PvDBP in healthy adults living in the UK
    Medical condition: Plasmodium vivax malaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10047665 Vivax malaria (benign tertian) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-000099-27 Sponsor Protocol Number: HEAT01 Start Date*: 2017-04-26
    Sponsor Name:The Department of Urology
    Full Title: Toxicity of first-line abiraterone versus enzalutamide in men with metastatic castration-resistant prostate cancer: A randomized clinical trial
    Medical condition: Metastisc castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004964-25 Sponsor Protocol Number: ABY-035-203 Start Date*: 2021-05-21
    Sponsor Name:Affibody AB
    Full Title: A phase 2 trial of the efficacy and safety of the interleukin-17A inhibitor ABY-035 in the treatment and prevention of relapse/recurrence of non-infectious intermediate, posterior or pan-uveitis (L...
    Medical condition: non-infectious intermediate, posterior, or pan-uveitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005720-11 Sponsor Protocol Number: VAC31518COV3006 Start Date*: 2021-04-22
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Observer-blind, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in Healthy ...
    Medical condition: Healthy Volunteers (Prevention of SARS-CoV-2-mediated COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000924-32 Sponsor Protocol Number: AGMT_MM-3 Start Date*: 2018-12-07
    Sponsor Name:AGMT gGmbH
    Full Title: Denosumab for high risk SMM and SLiM CRAB positive, early myeloma patients- a randomized, placebo controlled phase II trial “DEFENCE” (DEnosumab For the rEductioN of the smoldering myeloma transfor...
    Medical condition: High-risk smouldering multiple myeloma or "SLiM CRAB" positive early multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067386 Multiple myeloma transformation LLT
    20.0 100000004864 10075894 Smoldering myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-000502-26 Sponsor Protocol Number: TAK-660-3001 Start Date*: 2025-02-13
    Sponsor Name:Baxalta US Inc.
    Full Title: A Phase 3, Prospective, Multicenter, Open-label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (ADYNOVATE) Administered for Prophylaxis and Treatment of Bleedi...
    Medical condition: Severe Hemophilia A (FVIII <1%)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 07:05:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA